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Abstract
Purpose Prior results from the registration system oncological gynecology (ROGY) care trial showed that survivorship care 
plans (SCPs) increased threatening illness perceptions in gynecological cancer survivors, but it remained unclear whether 
this would result in poorer physical and psychosocial outcomes. The aim of the current study is to assess the direct and 
indirect effects of SCPs on health-related quality of life (HRQoL) and anxiety and depression, through illness perceptions.
Methods Twelve hospitals in the South of the Netherlands were randomized to providing ‘SCP care’ or ‘usual care.’ Newly 
diagnosed endometrial and ovarian cancer patients completed questionnaires after initial treatment (endometrial, 221 [75%]; 
ovarian, 174 [71%]) and after 6, 12, and 24 months. SCPs were automatically generated after initial treatment by the oncology 
providers through the web-based ROGY. Illness perceptions were measured after initial treatment and HRQoL and anxiety 
and depression after 6, 12, and 24 months.
Results Structural equation models showed that endometrial cancer patients who experienced more symptoms or concern 
due to the SCP reported worse social functioning (β = − 0.82; p = 0.01) and more fatigue, insomnia, pain, and anxiety 
(β = 0.58–0.86, p < 0.05) within 12 months after treatment. Ovarian cancer patients who had lower trust that the treatment 
would cure their disease due to the SCP reported worse emotional functioning 6 months after treatment (β = 0.27, p = 0.02).
Conclusions Current results show that SCPs may have negative effects on HRQoL and anxiety in patients who experience 
more threatening illness perceptions due to the SCP. We should be aware of the potential negative consequences of SCPs.
Trial Registration clinicaltrials.gov Identifier: NCT01185626.
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Anxiety
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Background
Over the last decade, survivorship care plans (SCPs) 
have been recommended as a standard of care for all can-
cer patients. SCPs contain written information to support 
patients in their physical and psychological challenges in 
life after treatment [1]. To date, a limited number of ran-
domized controlled trials (RCTs) have been conducted to 
assess the impact of SCPs on patient reported outcomes 
[2–7]. As opposed to observational and qualitative studies 
[8, 9], RCTs failed to identify beneficial effects of SCPs 
on patient satisfaction with information provision and care, 
quality of life, or distress [2–5, 7]. However, SCPs may be 
beneficial for underserved patient populations [6]. The reg-
istration system oncological gynecology (ROGY) care trial 
was the first pragmatic cluster-randomized controlled trial 
that assessed the impact of automatically generated SCPs, 
and did find a negative effect on illness perceptions [5, 7].
Illness perceptions are generally defined as a patient’s 
belief about the disease through cognitive representations, 
including the perceived impact on life, duration of the ill-
ness, experienced symptoms and treatment trust, and also 
emotional representations, including concern, emotional 
impact, and personal control over illness [10]. In the ROGY 
care trial, SCPs caused more threatening illness perceptions: 
they increased experienced symptoms, emotional impact and 
concern in endometrial cancer patients [5], and led to lower 
trust that the treatment would help to cure the disease in 
ovarian cancer patients [7].
Previous studies in cancer patients show that more threat-
ening illness perceptions are associated with poorer qual-
ity of life and more psychological morbidities [11–17] in 
accordance with Leventhals’ common-sense model of self-
regulation (CSM). CSM presumes that individuals who are 
confronted with a health threat (i.e., cancer diagnosis) form 
illness perceptions, which impact physical and psychosocial 
outcomes through coping responses [10, 18]. To support 
emotional coping, psychological interventions have been 
developed that aim to decrease psychological distress after 
an event such as a cancer diagnosis [19]. Exposure therapies, 
such as psychological debriefing do not seem to decrease 
psychological morbidity, but may even worsen it due to 
exacerbation of the symptoms [20]. Similarly, SCPs contain-
ing extensive information on the disease and potential side-
effects may exacerbate psychological distress and symptoms 
experienced among cancer patients. Consequently, prior 
results of the ROGY care trial suggest that SCPs may inter-
vene in the pathway of the CSM by causing more threatening 
illness perceptions [5, 7], which may in turn affect physical 
and psychosocial outcomes. However, no evidence exists on 
the possible causal relationships between SCP provision, ill-
ness perceptions, and physical and psychosocial outcomes. It 
is important to consider the potential negative consequences 
of threatening illness perceptions due to SCPs before wide-
spread implementation is decided upon.
The aim of the current study is to assess whether SCPs 
have a negative effect on long-term health-related quality 
of life (HRQoL), anxiety and depression in patients who 
experience more threatening illness perceptions due to the 
SCP. Illness perception scales that have earlier shown to be 
affected by SCPs [5, 7] (i.e., increased experienced symp-
toms, concern and emotional impact in endometrial cancer, 
and lower treatment trust in ovarian cancer) are included 
in the current analysis. We hypothesize that SCPs have a 
negative impact on HRQoL, anxiety and depression through 
more threatening illness perceptions.
Methods
Design
The ROGY care trial among endometrial and ovarian cancer 
patients aimed to assess the longitudinal impact of auto-
matically generated SCPs on patient reported outcomes. A 
cluster-randomized design was used to avoid potential con-
tamination between the trial arms. Twelve hospitals in the 
Netherlands were randomly allocated to either ‘usual care’ 
or ‘SCP care.’ The trial was centrally approved by a Medi-
cal Research Ethics Committee [21] and was registered as 
NCT01185626 in clinicaltrials.gov.
Participants and recruitment
All newly diagnosed women with endometrial cancer as a 
primary tumor between April 2011 and October 2012, or 
ovarian cancer between April 2011 and March 2014, were 
invited to participate shortly after initial treatment, by means 
of a letter and an informed consent form, sent directly to 
the patients’ home address by their own gynecologist. After 
consent, questionnaires were sent after treatment and follow-
up questionnaires were sent at 6, 12, and 24 months after 
treatment (“Appendix”). Because of the pragmatic nature of 
the trial, exclusion criteria (i.e., borderline ovarian tumor, 
undergoing palliative care or unable to complete a Dutch 
questionnaire) were limited [21]. Earlier analysis showed 
that 73% of endometrial and 66% of ovarian cancer patients 
in the SCP care arm reported receipt of an SCP [22]. In the 
current analysis, all patients of both trial arms were included 
(intention-to-treat) to reflect real-life clinical practice in 
which not all patients receive an SCP.
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Randomization and blinding
To prevent imbalance between the trial arms, stratified ran-
domization was used according to whether a hospital has a 
Gynecologic Oncology Center, and the annual number of 
endometrial and ovarian cancer patients diagnosed in each 
hospital. Randomization was performed via a table of ran-
dom numbers, by an independent researcher blinded to the 
identity of the hospitals. Patients, but not oncology providers 
or researchers assessing the outcomes, were blinded to trial 
assignment [21].
SCP care versus usual care
In ‘usual care’ hospitals, standard care was provided in 
accordance to the Dutch follow-up guidelines (http://www.
oncol ine.nl). In most hospitals, verbal information and the 
generic brochures of the Dutch Cancer Society were pro-
vided [21]. None of the hospitals provided SCPs as devel-
oped for this study.
In the ‘SCP care’ hospitals, all oncology providers 
(gynecologist/gynecologic oncologist and oncology nurses, 
N = 24) attended an instruction evening devoted to when and 
how SCPs should be provided. They were instructed to pro-
vide an SCP to patients at the consultation where the results 
of histopathology and (adjuvant) treatment plan were dis-
cussed, mostly 7–14 days after surgery. If applicable (i.e., if 
there were any changes in the cancer, treatment or oncology 
provider), an updated version of the SCP could optionally be 
discussed in a follow-up consultation. Practical guidelines 
were given on the components of the SCP that should mini-
mally be discussed with each patient during the consultation 
(i.e., diagnosis, prognosis, treatment(s), most important side-
effects). Because of the pragmatic approach of the trial, care 
providers in the ‘SCP care’ arm were free to choose whether 
the gynecologist/gynecologic oncologist, or oncology nurse 
provided the SCP fitting their clinical practice [21].
Survivorship care plan
The SCP was based on the Dutch translation of the National 
Academy of Medicine (NAM) SCP template [1], adjusted to 
the local situation [21] by a group of gynecologists/gyneco-
logic oncologists, oncology nurses, a radiotherapist, medical 
oncologist, primary care physician, and patients [21]. The 
SCP consisted of information on diagnostic tests, type of 
cancer, stage, grade, and treatments received, and contact 
details of the hospital and medical specialists. In addition, 
the SCP contained a tailored follow-up care plan, includ-
ing detailed information on the most common short- and 
long-term effects of the treatments received, effects on social 
and sexual life, possible signs of recurrence and secondary 
tumors, and information on rehabilitation, psychosocial sup-
port, and supportive care services [21]. Texts of the SCP 
were based on pilot-tested patient education material from 
the Dutch Cancer Society. In addition, the SCP was pilot-
tested on patients with a low/intermediate educational level 
to ensure that the SCP was understandable.
Measures
Age, socio-economic status (SES), and clinical data, such 
as cancer type, cancer stage, and date of diagnosis, were 
obtained from the Netherlands Cancer Registry (NCR). 
The NCR routinely collects data on newly diagnosed can-
cer patients in all hospitals in the Netherlands [23]. SES was 
based on postal code of the residence area of the patient, 
combining aggregated individual fiscal data on the economic 
value of the home and household incomes [24]. SES was 
categorized into low, medium, or high. Additional socio-
demographic information (i.e., marital status, employment 
status, and comorbidities) was assessed in the first question-
naire. Marital status (‘married/living together’ vs ‘divorced/
widowed/never married’) and employment status (‘having 
a paid job’ vs ‘not having a paid job’) were dichotomized. 
Comorbidity was assessed by the adapted Self-administered 
Comorbidity Questionnaire (SCQ), and categorized into no 
comorbidities, one comorbidity, or more than one comor-
bidity [25].
The Brief Illness Perception Questionnaire (B-IPQ) was 
used to assess illness perceptions after initial treatment [26]. 
The B-IPQ includes eight single-item scales (impact of dis-
ease on life, perceived duration of illness, personal control 
over illness, trust that the treatment would help to cure the 
illness, experienced symptoms, concern about the illness, 
understanding of the illness, and emotional impact of the ill-
ness). Only the scales that have earlier shown to be affected 
by SCPs in our trial [5, 7] were used in the analysis, includ-
ing the amount of symptoms experienced, concerns about 
the illness, emotional impact of the illness with respect to 
endometrial cancer, and trust that the treatment would help 
to cure with respect to ovarian cancer [27]. The latter scale 
was reversed to ascertain that all B-IPQ scales were one-
directional: a higher score indicates more threatening ill-
ness perceptions. Test–retest reliability (Pearson correlations 
0.42–0.75) was fair [26].
The EORTC QLQ-C30 (version 3.0) was used to assess 
HRQoL 6, 12, and 24 months after diagnosis [28]. It contains 
five functional scales on physical, role, cognitive, emotional 
and social functioning, a global QoL scale; three symptom 
scales on fatigue, nausea and vomiting, and pain; and six 
single items. Response scales included: ‘Not at all,’ ‘A bit,’ 
‘Quite a bit,’ and ‘Very much,’ except for the global QoL 
scale, which ranges from ‘Very poor’ to ‘Excellent.’ Latent 
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variables of the scales were defined by the items of each 
scale [29]. Higher scores on global quality of life and the 
function scales indicate a better HRQoL, while higher scores 
on the symptom scales indicate more symptoms. Test–retest 
reliability was good (Pearson correlations = 0.82–0.91) [30]. 
Internal consistency of the multi-item scales (Cronbach’s 
alphas 0.71–0.92) in our study was good.
The Hospital Anxiety and Depression Scale (HADS) was 
used to assess symptoms of anxiety and depression 6, 12, 
and 24 months after diagnosis [31]. The HADS assesses 
separate anxiety and depression scales, which both consist 
of seven items. All items were scored on a 0–3-point scale, 
with higher scores indicating more symptoms. Test–retest 
reliability of the scales (Pearson correlations = 0.86–0.88) 
was good [31]. Internal consistency of the scales (Crohn-
bach’s alphas 0.71–0.77) in our study was good.
Statistical analysis
Statistical analyses were conducted using Statistical Anal-
ysis System (SAS) version 9.4. (SAS Institute, Cary, NC, 
1999). Differences in characteristics of patients between the 
trial arms for endometrial and ovarian cancer were com-
pared using independent samples t tests for normally dis-
tributed continuous variables, Mann–Whitney U tests for 
not normally distributed variables and Chi-square tests for 
categorical variables. Differences in baseline B-IPQ scores 
between the trial arms were assessed using Chi-square tests 
of categorical variables defined by the 25th, 50th, 75th, and 
100th percentile scores of the separate B-IPQ scales.
Pearson’s correlation coefficients were computed to 
assess the correlations between the illness perception scales 
at baseline and outcomes (HRQoL, anxiety and depression) 
6, 12, and 24 months after initial treatment, for endometrial 
and ovarian cancer separately. P values smaller than .05 
were considered to be statistically significant.
Structural equation models (SEM) were used to test the 
hypothesized causal relationships between trial allocation 
(SCPs), illness perceptions and the HRQoL, and anxiety 
and depression scales, with a linear equation system. SEMs 
are used to assess unobservable ‘latent’ variables by using 
observed variables, and to assess the relationships between 
those (observed and latent) variables [32]. Both direct and 
indirect effects of trial allocation on outcome variables were 
assessed using the effpart statement in the CALIS proce-
dure in SAS. Direct effects would indicate an effect of SCPs 
on the outcome scales in all patients, while indirect effects 
would indicate an effect of SCPs on the outcome scales in 
patients who have altered illness perceptions due to the SCP. 
Statistical power was sufficient to detect indirect effects, but 
low to detect direct effects [33]. The CALIS procedure was 
used to define the model paths (i.e., hypothesized relation-
ships between variables). First, simple mediation models 
were built to assess the direct and indirect effects of trial 
allocation on the separate outcome scales (HRQoL, anxi-
ety and depression scales) 6, 12, and 24 months after initial 
treatment. Mediators were the separate B-IPQ scales meas-
ured after initial treatment that have earlier shown to be asso-
ciated with trial allocation (i.e., increased experienced symp-
toms, concern and emotional impact in endometrial cancer, 
and lower treatment trust in ovarian cancer; Fig. 1). Models 
were defined for endometrial and ovarian cancer separately. 
The paths in each simple mediation model were defined as 
trial allocation ---> [BIPQ item score after diagnosis] ---> 
[outcome variable at time-point X]. When outcome scales 
consisted of multiple items, a latent variable was defined 
by the items of that scale. When standardized factor load-
ings of scale items were low (β < 0.6), they were removed 
from the model to obtain a better model fit [34]. When 
(semi-)complete separation of the outcome scales occurred, 
no SEM could be determined [35]. Second, the full SEMs 
were built by entering all significant paths (p < 0.05) of the 
simple mediation models into one model, for endometrial 
and ovarian separately, and for each time-point separately. 
Third, the insignificant paths (p > 0.05) were removed from 
the model to obtain a good model fit. Finally, the covariates 
that were significantly associated with any of the outcome 
scales were entered into the model. For all SEM models, full 
information maximum likelihood (FIML) was used, which 
handles missing data within the model without needing to 
impute data [36]. Model fit was assessed with the χ2 statistic, 
adjusted goodness-of-fit-index (AGFI), Bentler’s Compara-
tive Fit Index (CFI), standardized root mean squared resid-
ual (SRMR), and root mean squared error approximation 
(RMSEA) [37]. Standardized beta coefficients were used to 
interpret the models, and range from − 1 to 1, in which coef-
ficients closer to zero indicate smaller effects. An increase of 
1 standard deviation of the independent variable corresponds 
to an increase in standard deviation of the dependent vari-
able by the standardized beta coefficient [38]. Standardized 
beta coefficients of indirect effects can be considered small 
(0.05–0.10), moderate (0.1–0.25), or large (> 0.25) [38].
Results
Table 1 shows the clinical and socio-demographic baseline 
characteristics for both endometrial and ovarian cancer 
patients in the SCP care and usual care conditions. In endo-
metrial cancer, patients in the ‘SCP care’ took more time 
after diagnosis to complete the questionnaires than patients 
in the ‘Usual care’ arm (p < 0.01). No differences in baseline 
characteristics were found between the trial arms in ovarian 
cancer patients.
Figure 1 shows the differences in illness perceptions 
between the SCP care and usual care arms. Significantly 
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more endometrial patients in the SCP care arm compared 
to the usual care arm reported high experienced symptoms 
(18% vs 9%, p = 0.02) and high concerns about the illness 
(16% vs 7%, p = 0.02). No significant differences between 
the trial arms were found in emotional impact of the disease 
(19% vs 14%, p = 0.27) in endometrial cancer, or low trust 
that the treatment would help to cure the illness (16% vs 14%, 
p = 0.60) in ovarian cancer. However i,n earlier multilevel 
linear mixed model analyses, SCPs significantly increased 
threatening illness perceptions on these scales [5, 7].
Table 2 shows the correlations between illness perception 
scales after diagnosis and HRQoL, anxiety and depression 
after 6, 12, and 24 months, corrected for multiple testing 
(Bonferroni correction, α < 0.003). Consistent with our 
hypothesis, in both endometrial and ovarian cancer, signifi-
cant moderate negative Pearson’s correlations were found 
between B-IPQ items and functioning scales (r = − 0.25 to 
− 0.41, p < 0.003). Significant moderate positive Pearson’s 
correlations were found between B-IPQ items and symptom 
scales (r = 0.27–0.41, < 0.003), and between B-IPQ scales 
and anxiety and depression (r = 0.28–0.46, < 0.003).
The SEM models showed no direct effects of SCPs on 
HRQoL, anxiety and depression scales. However, indirect 
effects through illness perceptions were observed. In endo-
metrial cancer, SCPs indirectly increased fatigue, insom-
nia, and anxiety after 6 months (standardized, β = 0.58, 
SE = 0.09, p < 0.01; β = 0.69, SE = 0.08, p < 0.01; β = 0.58, 
SE = 0.09, p = 0.01), through more experienced symptoms 
(standardized, β = 0.21, SE = 0.09, p = 0.02; Fig. 2). Model 
fit was reasonable to good (AGFI = 0.87; CFI = 0.93; 
SRMR = 0.07; RMSEA = 0.047 [95% CI = 0.03–0.06]; 
χ2 = 87.2, p < 0.01) and effect sizes of the indirect effects 
are moderate (standardized, β = 0.12, SE = 0.06, p = 0.03; 
β = 0.15, SE = 0.06, p = 0.02; β = 0.12, SE = 0.05, p = 0.03) 
[38]. Further, SCPs indirectly decreased social function-
ing after 12 months (standardized, β = − 0.82, SE = 0.06, 
p < 0.01), and increased fatigue and pain after 12 months 
(standardized, β = 0.84, SE = 0.05, p < 0.01; β = 0.86, 
SE = 0.05, p < 0.01), through more concern (standardized, 
β = 0.25, SE = 0.09, p < 0.01; Fig. 2). Model fit was good 
(AGFI = 0.90; CFI = 0.98; SRMR = 0.046; RMSEA = 0.04 
[95% CI = 0.00–0.06]; χ2 = 34.4, p = 0.08) and the effect 
sizes of the indirect effects were moderate (standardized, 
β = − 0.20, SE = 0.07, p < 0.01; β = 0.21, SE = 0.07, p < 0.01; 
β = 0.22, SE = 0.08, p < 0.01) [38]. In ovarian cancer, SCPs 
indirectly decreased emotional functioning after 6 months 
Fig. 1  Bar charts of illness 
perceptions after diagnosis, 
SCP care (SCP) versus usual 
care (UC). Note only the illness 
perception items were included 
that have earlier been associated 
with trial allocation. High, med-
high, med-low, and low illness 
perception categories were 
defined by the 25th, 50th, 75th, 
and 100th percentile scores of 
each B-IPQ scale separately
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(standardized, β = − 0.66, SE = 0.20 p < 0.01), through 
lower trust that the treatment would help to cure the dis-
ease (standardized, β = 0.27, SE = 0.12, p < 0.05) (Fig. 2). 
Model fit was good (AGFI = 0.90; CFI = 0.96; SRMR = 0.06; 
RMSEA = 0.06 [95% CI = 0.01–0.09]; χ2 = 23.1, p = 0.04), 
and the effect size of the indirect effect was moderate 
(standardized, β = − 0.18, SE = 0.08, p = 0.02) [38]. No sig-
nificant paths in the simple mediation models were found for 
outcomes after 24 months, for both endometrial and ovarian 
cancer.
Table 1  Baseline clinical and socio-demographic characteristics endometrial and ovarian cancer patients, SCP care versus usual care
P values < 0.05 are in bold
a Socio-economic status (SES) was based on postal code of the residence area of the patient
b Marital status included: partner married/living together; no partner divorced/widowed/never married. The numbers may not always add up to 
100, because percentages have been rounded off to whole numbers
Endometrial cancer Ovarian cancer
SCP care (N = 119) Usual care (N = 102) P value SCP care (n = 61) Usual care (n = 113) P value*
Age at survey
 Mean (SD) 67.4 (9.1) 67.8 (8.9) 0.71 63.6 (11.2) 64.3 (10.7) 0.67
SESa, n (%)
 High 43 (36) 36 (35) 0.60 25 (41) 44 (39) 0.12
 Intermediate 49 (41) 42 (41) 15 (25) 44 (39)
 Low 21 (18) 22 (22) 12 (20) 18 (16)
 Unknown 6 (5) 2 (2) 9 (15) 7 (6)
Months since diagnosis, n (%)
 Median 2.2 1.5 < 0.01 3.0 2.4 0.31
 < 1 12 (10) 24 (24) 8 (13) 26 (23)
 1–2 40 (34) 46 (45) 18 (30) 39 (34)
 2–3 33 (28) 20 (20) 8 (13) 17 (15)
 > 3 34 (29) 12 (12) 27 (44) 32 (28)
Comorbidity, n (%)
 None 19 (16) 18 (18) 0.53 21 (34) 28 (25) 0.18
 1 32 (27) 20 (20) 12 (20) 36 (32)
 2 or more 64 (54) 62 (61) 26 (43) 48 (36)
 Unknown 4 (3) 2 (2) 2 (3) 8 (7)
Marital  statusb, n (%)
 Partner 85 (71) 76 (75) 0.74 48 (79) 82 (73) 0.39
 No partner 31 (26) 25 (25) 13 (21) 31 (27)
 Unknown 3 (3) 1 (1) 0 (0) 0 (0)
Employed, n (%)
 Yes 22 (18) 15 (15) 0.40 20 (33) 31 (27) 0.44
 No 85 (71) 79 (77) 41 (67) 83 (73)
 Unknown 12 (10) 8 (8) 0 (0) 0 (0)
FIGO stage, n (%)
 I 102 (85) 89 (87) 0.34 21 (34) 31 (27) 0.63
 II 6 (5) 1 (1) 7 (11) 9 (8)
 II 9 (8) 9 (8) 23 (38) 50 (44)
 IV 2 (2) 3 (3) 10 (16) 20 (18)
 Unknown 0 (0) 0 (0) 0 (0) 3 (3)
Treatment, n (%)
 Surgery 117 (99) 97 (98) 0.46 54 (88) 104 (93) 0.33
 Chemotherapy 6 (5) 12 (12) 0.06 44 (72) 92 (82) 0.13
 Radiotherapy 44 (37) 37 (37) 0.99
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Discussion
The current study among endometrial and ovarian cancer 
patients shows that SCPs have a negative impact on long-
term HRQoL and anxiety in patients who experience more 
threatening illness perceptions due to the SCP. Endometrial 
cancer patients who experience more symptoms or concerns 
due to the SCP, report worse social functioning and more 
fatigue, insomnia, pain, and anxiety in the year following 
treatment. Ovarian cancer patients who have lower trust 
that the treatment would cure their disease, due to the SCP, 
report worse emotional functioning 6 months after initial 
treatment.
Earlier findings from the ROGY Care trial already 
showed that SCPs increased threatening illness percep-
tions: higher experienced symptoms, concern and emotional 
impact in endometrial cancer patients, and decreased trust 
that the treatment would help to cure the disease in ovarian 
cancer patients [5, 7]. However, it was yet unclear whether 
these threatening illness perceptions would deteriorate long-
term physical and psychosocial outcomes. Our study con-
firms earlier findings in cancer patients that more threatening 
illness perceptions are associated with worse physical and 
psychosocial outcomes [11–17]. Consequently, our analy-
ses confirmed that threatening illness perceptions due to the 
SCP led to worse HRQoL and more anxiety. Although no 
direct effects of SCPs were found, our results support our 
hypothesis that SCPs have a negative impact on HRQoL 
and anxiety through more threatening illness perceptions, 
consistent with Leventhal’s CSM [10].
Illness perceptions that mediated between SCP provi-
sion and HRQoL and anxiety were experienced symptoms 
and concern in endometrial cancer, and low treatment trust 
in ovarian cancer patients. Possibly, endometrial cancer 
Table 2  Correlations between illness perception scales after diagnosis and HRQoL, anxiety and depression after 6, 12, and 24 months
Pearson’s correlations were estimated between illness perceptions measured after diagnosis, and outcome variables after diagnosis and 6, 12, and 
24 months after diagnosis. Only the illness perception items were included that have earlier been associated with trial allocation
* p < 0.003 (adjusted for Bonferroni correction 0.05/1)
Endometrial cancer Ovarian cancer
Illness perceptions after 
treatment
Symptoms experienced Concerns Emotional impact Lower treatment trust
Months after treatment, 
outcome variables
6 18 24 6 18 24 6 18 24 6 18 24
N 158 147 128 158 147 128 158 147 128 124 101 75
Global quality of life − 0.24 − 0.25* − 0.21 − 0.25* − 0.29* − 0.34* − 0.29* − 0.29* − 0.29* − 0.42* − 0.40* − 0.36*
Function scales
 Physical functioning − 0.22 − 0.19 − 0.24 − 0.14 − 0.21 − 0.19 − 0.18 − 0.22 − 0.18 − 0.24 − 0.16 − 0.16
 Role functioning − 0.06 − 0.20 − 0.28* − 0.09 − 0.15 − 0.36* − 0.22 − 0.13 − 0.25 − 0.27 − 0.18 − 0.25
 Emotional functioning − 0.34* − 0.21 − 0.32* − 0.32* − 0.24 − 0.38* − 0.38* − 0.29* − 0.41* − 0.28* − 0.15 − 0.27
 Cognitive functioning − 0.17 − 0.07 − 0.25 − 0.14 − 0.17 − 0.28* − 0.17 − 0.06 − 0.22 − 0.19 − 0.29 − 0.34
 Social functioning − 0.41* − 0.28* − 0.32* − 0.23 − 0.29* − 0.38* − 0.33* − 0.27* − 0.27* − 0.16 − 0.07 − 0.26
Symptom scales
 Fatigue 0.36* 0.28* 0.34* 0.26 0.26 0.37 0.35* 0.31* 0.32* 0.26 0.14 0.29
 Nausea and vomiting 0.13 0.21 0.24 0.06 0.05 0.14 0.15 0.09 0.12 0.14 0.15 0.33
 Pain 0.23 0.17 0.26 0.20 0.23 0.39* 0.22 0.20 0.26 0.28* 0.19 0.33
 Dyspnea 0.18 0.19 0.11 0.07 0.14 0.14 0.15 0.15 0.20 0.20 0.02 0.23
 Insomnia 0.32* 0.17 0.25 0.23 0.19* 0.28* 0.30* 0.22 0.26 0.31* 0.20 0.18
 Appetite loss 0.28* 0.16 0.23 0.18 0.03 0.28* 0.27* 0.14 0.24 0.22 0.09 0.44*
 Constipation 0.04 0.03 0.09 0.11 0.02 0.22 0.14 0.08 0.22 0.21 0.21 0.14
 Diarrhea 0.18 0.11 0.13 0.15 0.11 0.05 0.21 0.08 0.14 0.06 < 0.01 0.13
 Financial difficulties 0.30* 0.20* 0.20 0.17 0.08 0.11 0.21 0.10 0.08 0.16 0.09 − 0.08
Anxiety 0.30* 0.33* 0.34* 0.41* 0.45* 0.46* 0.46* 0.47* 0.45* 0.39* 0.31 0.24
Depression 0.39* 0.28* 0.23* 0.35* 0.35* 0.36* 0.39* 0.33* 0.34* 0.40* 0.25 0.38*
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patients, who are often diagnosed with low cancer stages, 
may perceive their cancer as a more serious condition due 
to information provided in the SCP (i.e., the diagnosis and 
treatments received, possible long-term and late effects, and 
chance of recurrence) than would otherwise be communi-
cated by the oncology provider. The overall perception of a 
more serious condition in endometrial cancer patients may 
have caused higher symptom awareness, more anxiety, and 
the belief that one is unable to participate in social activi-
ties [16]. In ovarian cancer patients, who are more often 
diagnosed at advanced stages, the SCP led to lower treat-
ment trust, possibly due to information on chance of recur-
rence in the SCP. Although this information may be realistic, 
it led to decreased emotional functioning after 6 months, 
meaning that patients felt more tense, worried, irritable, or 
depressed. Indeed, fear of recurrence has earlier been found 
to be most strongly associated with emotional functioning, 
of all EORTC QLQ-C30 functioning scales [39].
A limitation of the current study is that not all patients 
in the SCP arm reported receipt of an SCP [22]. A process 
evaluation of the ROGY care trial showed that ovarian can-
cer patients, older patients, and patients who have a dis-
tressed (type D) personality less often received an SCP [22]. 
We performed intention-to-treat analysis to reflect real-life 
clinical practice in which not all patients receive an SCP. 
Therefore, our results possibly underestimate the effects of 
SCPs on HRQoL, anxiety and depression in the total popu-
lation, as patients with a type D personality may be more 
likely to experience threatening illness perceptions due to 
the SCP [40]. Further, as shown earlier [7], ovarian cancer 
patients with higher cancer stages were more often lost to 
follow-up due to death or ill-health, and were therefore not 
included in our longitudinal analyses. Therefore, current 
results in ovarian cancer may represent the healthier patient 
with lower cancer stages. However, we aimed to minimize 
selection bias by limiting exclusion criteria and our response 
rates were relatively high.
Our SEM analyses violated the well-known recommen-
dation of Baron and Kenny’s that a significant relationship 
between the independent variable (SCPs) and outcome 
(HRQoL, anxiety and depression) is required, in order to 
evaluate mediation effects [41]. However, this recommen-
dation has since been criticized [33, 42]. Kenny and Judd 
argued that sample sizes needed to detect direct effects 
between independent and dependent variables, should be 
much larger than to detect indirect effects through mediation 
[33]. Therefore, our sample sizes of endometrial and ovar-
ian cancer separately, were too small to detect direct effects 
of SCPs on the outcome scales. Possibly, direct effects of 
SCPs on the outcome scales would be found in larger sam-
ple sizes. An alternative explanation of our findings is the 
presence of a suppressing mediator, such as coping, which 
may ameliorate the indirect impact of SCPs on physical 
and psychological outcomes, while at the same time illness 
perceptions deteriorate the indirect impact of SCPs on out-
comes. Therefore, there may be indirect effects but no direct 
effects of SCPs on HRQoL and anxiety [42], which would 
Fig. 2  Path diagrams of the final structural equation models, out-
comes 6 and 12  months after treatment. Note only the significant 
paths between the intervention (SCP), illness perception items, and 
outcome scales were entered in this model to obtain good model fit. 
Standardized coefficients are shown. Standardized beta coefficients 
were used to interpret the models, and range from − 1 to 1, in which 
coefficients closer to zero indicate smaller effects. Error terms and 
covariates in the model (age, FIGO stage, number of comorbidities) 
have been removed from the figure. *p < 0.05; **p < 0.01
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indicate that the impact of SCPs works differently across 
coping styles.
In earlier publications of the ROGY care trial [5, 7], we 
argued that information provided in an SCP could be per-
ceived as threatening but may also be realistic. Providing 
patients with honest and realistic information may be con-
sidered best to prepare patients for potential consequences 
of the cancer and cancer treatments, or would encourage 
patients to find social support to cope with the disease [43]. 
However, the current study shows that realistic informa-
tion is not self-evidently beneficial for all patients. Instead, 
patients may attain worse expectations about negative out-
comes such as side-effects or a recurrence, which has shown 
to potentially cause clinical worsening (“nocebo effect”) 
[44]. Similarly, psychological interventions that expose 
individuals to facts and rethinking of an event (i.e., can-
cer diagnosis and treatments) may not necessarily decrease 
psychological distress but rather exacerbate symptoms [20]. 
Possibly, patients with certain personality types or coping 
styles may be more vulnerable to the harmful effects of 
exposure interventions such as SCPs. On the other hand, one 
may argue that patients benefit from having received realistic 
information on the chance of recurrence in an SCP, after 
they eventually develop a recurrence. Little is known about 
the effect of exposure to information about a potentially neg-
ative outcome, after the negative outcome has manifested. 
Unfortunately, numbers of patients with a recurrence in our 
trial were too small to investigate the impact of SCPs in 
these patients after diagnosis of a recurrence. Further mod-
eration analysis considering patient characteristics, personal-
ity, and coping style could further reveal which patients do, 
and which patients do not benefit from SCPs.
Conclusion
In conclusion, no beneficial effects of SCPs on satisfaction 
with information provision and care in both endometrial and 
ovarian cancer patients were shown as primary outcomes of 
our trial [5, 7]. The current study highlights that SCPs may 
even have negative effects on HRQoL and anxiety in patients 
who experience more threatening illness perceptions due 
to the SCP. Therefore, we should be aware of the potential 
negative consequences of SCPs in some patients. A more tai-
lored approach such as personalized SCPs fitting individual 
patient’s information needs should be further explored.
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Appendix
After treatment
Patients receiving questionnaire (n=245)
Endometrial (n=154), ovarian (n=91)
Patients completing questionnaire (n=180)
Endometrial (n=119), ovarian (n=61)
♦ Refused participation (n=65)
Endometrial (n=35), ovarian (n=30)
♦ Patients wanting to stop after 1 questionnaire (n=42)
Endometrial (n=32), ovarian (n=10)
After treatment
Patients receiving questionnaire (n=157)
Endometrial (n=142), ovarian (n=157)
Patients completing questionnaire (n=215)
Endometrial (n=102), ovarian (n=113)
Refused participation (n=84)
Endometrial (n=40), ovarian (n=44)
Patients wanting to stop after 1 questionnaire (n=42)
Endometrial (n=21), ovarian (n=21)
6 months
Patients receiving a questionnaire (n=138)
Endometrial (n=87), ovarian (n=51)
Patients completing the questionnaire (n=129)
Endometrial (n=85), ovarian (n=44)
♦ Refused participation: endometrial (n=2), ovarian (n=3)
♦ Deceased: endometrial (n=0), ovarian (n=4)
12 months
Patients receiving a questionnaire (n=134)
Endometrial (n=87), ovarian (n=47)
Patients completing the questionnaire (n=114)
Endometrial (n=79), ovarian (n=35)
♦ Refused participation: endometrial (n=7), ovarian (n=7)
♦ Deceased: endometrial (n=1), ovarian (n=5)
24 months
Patients receiving a questionnaire (n=110)
Endometrial (n=70), ovarian (n=40)
Patients completing the questionnaire (n=98)
Endometrial (n=69), ovarian (n=29)
♦ Refused participation: endometrial (n=8), ovarian (n=8)
♦ Deceased: endometrial (n=2), ovarian (n=4)
6 months
Patients receiving a questionnaire (n=172)
Endometrial (n=81), ovarian (n=91)
Patients completing the questionnaire (n=153)
Endometrial (n=73), ovarian (n=80)
♦ Refused participation: endometrial (n=7), ovarian (n=7)
♦ Deceased: endometrial (n=1), ovarian (n=4)
12 months
Patients receiving a questionnaire (n=167)
Endometrial (n=80), ovarian (n=87)
Patients completing the questionnaire (n=134)
Endometrial (n=68), ovarian (n=66)
♦ Refused participation: endometrial (n=10), ovarian (n=13)
♦ Deceased: endometrial (n=2), ovarian (n=8)
24 months
Patients receiving a questionnaire (n=140)
Endometrial (n=69), ovarian (n=71)
Patients completing the questionnaire (n=105)
Endometrial (n=59), ovarian (n=46)
♦ Refused participation: endometrial (n=10), ovarian (n=17)
♦ Deceased: endometrial (n=0), ovarian (n=12)
Follow-up
Patients analyzed
After treatment (n=180)
Endometrial (n=119), ovarian (n=61)
6 months follow-up (n=129)
Endometrial (n=85), ovarian (n=44)
12 months follow-up (n=114)
Endometrial (n=79), ovarian (n=35)
24 months follow-up (n=98)
Endometrial (n=69), ovarian (n=29)
Hospitals allocated to intervention (n=6)
♦ Received allocated intervention (n=6)
Patients analyzed
After treatment (n=215)
Endometrial (n=102), ovarian (n=113)
6 months follow-up (n=152)
Endometrial (n=73), ovarian (n=79)
12 months follow-up (n=133)
Endometrial (n=68), ovarian (n=65)
24 months follow-up (n=105)
Endometrial (n=59), ovarian (n=46)
Hospitals allocated to usual care (n=6)
♦ Received allocated usual care (n=6)
Analysis
Randomized hospitals (n=12)Enrollment
Enrollment of patients
Allocation
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